The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene
Neuregulin-1 ( NRG1 ) is both a candidate oncogene and a candidate tumour suppressor gene. It not only encodes the heregulins and other mitogenic ligands for the ERBB family, but also causes apoptosis in NRG1 -expressing cells. We found that most breast cancer cell lines had reduced or undetectable...
Gespeichert in:
Veröffentlicht in: | Oncogene 2009-11, Vol.28 (46), p.4041-4052 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Neuregulin-1
(
NRG1
) is both a candidate oncogene and a candidate tumour suppressor gene. It not only encodes the heregulins and other mitogenic ligands for the
ERBB
family, but also causes apoptosis in
NRG1
-expressing cells. We found that most breast cancer cell lines had reduced or undetectable expression of
NRG1
. This included cell lines that had translocation breaks in the gene. Similarly, expression in cancers was generally comparable to or less than that in various normal breast samples. Many non-expressing cell lines had extensive methylation of the CpG island at the principal transcription start site at exon 2 of
NRG1
. Expression was reactivated by demethylation. Many tumours also showed methylation, whereas normal mammary epithelial fragments had none. Lower
NRG1
expression correlated with higher methylation. Small interfering RNA (siRNA)-mediated depletion of
NRG1
increased net proliferation in a normal breast cell line and a breast cancer cell line that expressed
NRG1
. The short arm of chromosome 8 is frequently lost in epithelial cancers, and
NRG1
is the most centromeric gene that is always affected.
NRG1
may therefore be the major tumour suppressor gene postulated to be on 8p: it is in the correct location, is antiproliferative and is silenced in many breast cancers. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/onc.2009.259 |